CN102872008B - Aphanamixoid A在治疗白血病药物中的应用 - Google Patents
Aphanamixoid A在治疗白血病药物中的应用 Download PDFInfo
- Publication number
- CN102872008B CN102872008B CN201210413773.3A CN201210413773A CN102872008B CN 102872008 B CN102872008 B CN 102872008B CN 201210413773 A CN201210413773 A CN 201210413773A CN 102872008 B CN102872008 B CN 102872008B
- Authority
- CN
- China
- Prior art keywords
- aphanamixoid
- leukaemia
- cell
- application
- medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930193702 aphanamixoid Natural products 0.000 title claims abstract description 35
- 208000032839 leukemia Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 240000003906 Aphanamixis grandifolia Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000002630 limonoids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- -1 Tetramethyl azo azoles salt Chemical class 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210413773.3A CN102872008B (zh) | 2012-10-25 | 2012-10-25 | Aphanamixoid A在治疗白血病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210413773.3A CN102872008B (zh) | 2012-10-25 | 2012-10-25 | Aphanamixoid A在治疗白血病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102872008A CN102872008A (zh) | 2013-01-16 |
CN102872008B true CN102872008B (zh) | 2014-04-16 |
Family
ID=47473682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210413773.3A Active CN102872008B (zh) | 2012-10-25 | 2012-10-25 | Aphanamixoid A在治疗白血病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102872008B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1178793A (zh) * | 1997-10-31 | 1998-04-15 | 中国人民解放军第二军医大学药学院 | 一种新的抗癌活性化合物草苔虫内酯 |
CN102351823A (zh) * | 2011-07-28 | 2012-02-15 | 中国科学院新疆理化技术研究所 | 山莴苣素衍生物及其制备方法和用途 |
-
2012
- 2012-10-25 CN CN201210413773.3A patent/CN102872008B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1178793A (zh) * | 1997-10-31 | 1998-04-15 | 中国人民解放军第二军医大学药学院 | 一种新的抗癌活性化合物草苔虫内酯 |
CN102351823A (zh) * | 2011-07-28 | 2012-02-15 | 中国科学院新疆理化技术研究所 | 山莴苣素衍生物及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya;Jie-Yun Cai, et al.;《ORGANIC LETTERS》;20120427;第14卷(第10期);2524–2527 * |
Jie-YunCai et al..Aphanamixoid A |
Also Published As
Publication number | Publication date |
---|---|
CN102872008A (zh) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
He et al. | Anti-cervical cancer activity of secondary metabolites of endophytic fungi from Ginkgo biloba | |
CN105037464A (zh) | 一种植物黄酮类化合物及其制备方法与应用 | |
CN103585227B (zh) | 一种褐毛橐吾提取物在制备治疗白血病药物中的应用 | |
CN102872008B (zh) | Aphanamixoid A在治疗白血病药物中的应用 | |
CN106177187A (zh) | 具有增效减毒抗肝癌作用的茶多酚茶多糖组合物 | |
CN102872078B (zh) | Houttuynoid C在治疗白血病药物中的应用 | |
CN102872082B (zh) | Houttuynoid E在制备治疗白血病药物中的应用 | |
CN105287487A (zh) | Solanoeclepin A在制备治疗白血病药物中的应用 | |
CN102872113B (zh) | Houttuynoid A在治疗白血病药物中的应用 | |
CN102861053B (zh) | Houttuynoid D在治疗白血病药物中的应用 | |
YOKOZAWA et al. | Inhibitory effects of ginseng on proliferation of cultured mouse mesangial cells | |
CN103463064B (zh) | Lycojaponicumin C在制备治疗白血病药物中的应用 | |
CN103446134B (zh) | Lycojaponicumin A在制备治疗白血病药物中的应用 | |
CN103463019B (zh) | Lycojaponicumin B在制备治疗白血病药物中的应用 | |
CN103405456B (zh) | Chukrasone A在制备治疗白血病药物中的应用 | |
CN103405411B (zh) | Chukrasone B在制备治疗白血病药物中的应用 | |
CN103462962A (zh) | Incarviatone A在治疗白血病药物中的应用 | |
CN103393667A (zh) | Sarcaboside A在治疗白血病药物中的应用 | |
CN102861060A (zh) | Houttuynoid B在治疗白血病药物中的应用 | |
CN103356556A (zh) | Sarcaboside B在治疗白血病药物中的应用 | |
CN103520140A (zh) | 一种化合物在制备治疗白血病药物中的应用 | |
CN103301141A (zh) | Polyflavanostilbene A在制备治疗白血病药物中的应用 | |
CN103356634A (zh) | Aspeverin在制备治疗白血病药物中的应用 | |
CN107865884A (zh) | Orientin在制备治疗白血病药物中的应用 | |
CN106309431A (zh) | Linderolide H在制备治疗白血病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20141229 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210093 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141229 Address after: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Rudong science and Technology Center Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Patentee before: Nanjing University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200423 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee before: Rudong science and Technology Center |
|
TR01 | Transfer of patent right |
Effective date of registration: 20211220 Address after: Fengli town Xinjian West Road, Rudong County, Nantong City, Jiangsu Province 226400 Patentee after: Rudong Wenyuan investment and Development Co., Ltd Address before: 226400 No.10 Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |
|
TR01 | Transfer of patent right |